Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER Vancouver, BC, Canada, February 16th, 2022 -- InvestorsHub NewsWire Defence Therapeutics Inc...
Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9 Vancouver, BC, Canada, January 26th...
Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC: DTCFF) ("Defence" or the...
DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER Vancouver, BC, Canada -- November 23, 2021 -- InvestorsHub NewsWire...
DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS Vancouver, BC, Canada, November 9th, 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. CSE:DTC, USOTC:DTCFF...
VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS Vancouver, BC, Canada, November...
DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER Vancouver, BC, Canada, October 13th...
DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA Vancouver, BC, Canada, October 6th, 2021 -- InvestorsHub NewsWire -- Defence...
DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER Vancouver, BC, Canada, September 29th, 2021 - InvestorsHub NewsWire -- Defence Therapeutics Inc...
DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS Vancouver, BC, Canada, September 20th, 2021 -- InvestorsHub NewsWire -- Defence...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.12 | 17.6470588235 | 0.68 | 0.85 | 0.67 | 48002 | 0.79628515 | CS |
| 4 | 0.2 | 33.3333333333 | 0.6 | 0.85 | 0.6 | 35991 | 0.698225 | CS |
| 12 | 0.22 | 37.9310344828 | 0.58 | 0.85 | 0.49 | 27353 | 0.60959051 | CS |
| 26 | -0.07 | -8.04597701149 | 0.87 | 0.87 | 0.48 | 26803 | 0.61546159 | CS |
| 52 | -0.92 | -53.488372093 | 1.72 | 2.32 | 0.48 | 30994 | 0.99246723 | CS |
| 156 | -4.21 | -84.0319361277 | 5.01 | 5.25 | 0.48 | 20158 | 1.99523412 | CS |
| 260 | -0.95 | -54.2857142857 | 1.75 | 8.15 | 0.48 | 18899 | 2.47098834 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
